Lonza Divests Capsules & Health Ingredients Business for $3 Billion
Lonza signs agreement to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds, for an enterprise value of $3 billion (CHF 2.3 billion).
Lonza
Ethris and Lonza to Develop Spray-Dried mRNA Respiratory Vaccines
Ethris and Lonza have teamed up to develop room-temperature stable, spray-dried mRNA vaccines for respiratory diseases. This collaboration aims to create mucosal delivery formulations, offering a promising new approach to combat respiratory illnesses.
Lonza Outlines Restructuring Strategy and New Organizational Structure
At an investor update at the end of last week, Lonza has announced its "One Lonza" restructuring strategy, which aims to reorganize its CDMO business, simplify its operating model, enhance manufacturing and engineering, and expand its production footprint.
Lonza to Expand Bioconjugation in Visp, Switzerland
Lonza, a global contract development and manufacturing organization (CDMO) for the pharmaceutical, biotech, and nutraceutical markets, announced today that it will invest in additional bioconjugation capabilities in Visp, Switzerland.
Lonza Extends ADC Manufacturing Collaboration with Biopharma Company
Swiss contract development and manufacturing organization (CDMO) Lonza has announced a long-term extension of its collaboration with a key global biopharmaceutical partner for the manufacture of antibody-drug conjugates (ADCs) at commercial scale. The name of the partner was not disclosed.
Lonza Completes Acquisition of Vacaville Biologics Site from Roche
Lonza has completed its acquisition of the Genentech large-scale biologics manufacturing site in Vacaville, California, USA, from Roche for $1.2 billion. The deal was announced in March of this year.
Lonza and Vertex Sign a Commercial Supply Agreement for Casgevy
Lonza and Vertex Pharmaceuticals recently announced a commercial supply agreement for casgevy (exagamglogene autotemcel).
Lonza Launches Innovaform Accelerator
Lonza inaugurated its new facility at the Colmar, France site. The new Innovaform Accelerator will serve as a Center of Excellence for developing and innovating capsule-based manufacturing and delivery solutions for oral and pulmonary administration.
The Evolution of the CDMO Industry
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
The CDMO/CMO Report
Driven by increased demand in biologic-based drugs, biologic drug substance manufacturing continues to be an active area of investment by contract development and manufacturing organizations/contract manufacturing organizations (CDMOs/CMOs), including several multi-billion large-scale biomanufacturing projects. What companies are expanding, and where do these expansions stand?
Lonza Completes Expansion of Microbial Manufacturing Facility
Lonza recently announced that it has completed a planned expansion of the mid-scale microbial manufacturing facility at its Visp, Switzerland site. This multi-product facility was recently granted a GMP license, allowing cGMP manufacturing and release of biologics produced using microbial fermentation.
Expert Statement: Gordon Bates, Lonza
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Wolfgang Wienand to Join Lonza as New CEO
Lonza has appointed Wolfgang Wienand as its new CEO. He will join the company during the summer of 2024 and succeed Albert M. Baehny, who took on the additional responsibility of interim CEO in October 2023 while the search for a permanent CEO took place.
Large-Scale Production Announced by Epsilogen and Lonza for Ovarian Cancer Treatment
Epsilogen and Lonza have successfully completed the manufacturing of a potential cancer treatment. The complex process, which took less than ten months, was carried out at Lonza’s UK site following Good Manufacturing Practice (GMP) standards.
Lonza and Oxford Nanopore to Collaborate on mRNA Analysis
Swiss contract development and manufacturing organization (CDMO) Lonza will collaborate with Oxford Nanopore Technologies, a UK-based company delivering a new generation of nanopore-based molecular sensing technology. The collaboration aims to cGMP validate and commercialize a first-of-its-kind novel test to accurately determine multiple critical quality attributes of mRNA products by directly sequencing both the DNA template and the messenger RNA (mRNA).
Lonza Announces New Mid-Term Guidance 2024 – 2028
At its Capital Markets Day in Visp, Switzerland, Lonza shared a detailed update on its strategic priorities and provided new Mid-Term Guidance for 2024 to 2028.
Spray Drying for Inhalation: the Challenges of Scale-up
When developing an inhaled powder formulation, the drug particles’ properties are critical to successful delivery to the deep lung. The aerodynamic diameter is the key parameter, as it represents how well the particle flies in an air stream.
Lonza Increases Capacity for Antibody-Drug Conjugates at Visp, Switzerland
Swiss contract development and manufacturing organization (CDMO) Lonza is extending a long-term collaboration with an unnamed major global biopharmaceutical partner. Under the agreement, the current dedicated bioconjugation capacity will be increased fourfold by adding two new bioconjugation suites for the commercial supply of antibody-drug conjugates (ADCs) at Lonza's site in Visp, Switzerland.
The Evolution of CDMOs
Contract development and manufacturing organizations (CDMOs) are a crucial part of the life sciences industry. Strangely, despite its current prominence, the CDMO industry is a relatively young one. There have been significant developments over its short lifespan, and it is likely that we see even more growth in the years to come.
Lonza, Vertex Break Ground on New US Cell Therapy Plant
Last week, Lonza and Vertex Pharmaceuticals broke ground on a new US facility in Portsmouth, New Hampshire, to manufacture cell therapies for diabetes.
Lonza Acquires ADC Specialist Synaffix
Swiss CDMO Lonza has acquired Dutch-based Synaffix, a biotech focused on ADC development. The deal comprises an initial cash injection of €100 million and up to €60 million in additional performance-based considerations. Synaffix will continue to operate under its existing name.
Lonza to Add Early Development Services in US
Swiss CMDO Lonza said it will expand its Early Development Services (EDS) offering into North America with a new laboratory in Cambridge, Massachusetts, set to open in May this year.
Lonza Completes HPAPI Expansion at Visp
Lonza has completed of the expansion of its Highly Potent API (HPAPI) multipurpose suite at the Basel-based CDMO’s alpine production site in Visp, Switzerland, adding development and manufacturing capacity for ADC payloads.
Lonza and Touchlight Collaborate on DNA
Lonza has entered into a collaboration with Touchlight, a biotechnology company with patented technology for producing enzymatic DNA. The enzymatic manufacturing process is said to enable GMP production at “unprecented speed, scale and purity.”
Lonza Builds Swiss Fill & Finish Facility
Swiss CDMO Lonza plans to build a large-scale commercial fill & finish facility in Stein. The new facility, to be located on the same campus as Lonza’s existing clinical drug product capabilities, will cost roughly 500 million Swiss francs and should be completed in 2026.
Samsung Biologics in $81 Million Deal with Novartis
In the their first-ever collaboration, South Korea’s Samsung Biologics and Switzerland’s Novartis have inked an initial $81 million contract manufacturing and development deal, Samsung said in a regulatory filing.
Lonza and Israel Biotech Fund Collaborate
Lonza and Israel Biotech Fund (IBF) have signed a framework agreement, under which the Swiss CDMO will provide advice and support for Israeli biotech companies. IBF is dedicated to investing in and developing Israel’s biotech sector.
Integrated Drug Development Models
Interview with Giovanna Libralon, Senior Director Commercial Development Small Molecules at Lonza.
Germany’s Merck Takes Lonza’s MAST Platform
Germany’s Merck has acquired Lonza’s Modular Automated Sampling Technology (MAST) platform for an undisclosed sum. The Darmstadt-based chemicals, pharmaceuticals and life science group said the deal will advance its bioprocessing portfolio and complement two earlier acquisitions in this field.
Lonza to Manufacture Oasmia’s Ovarian Cancer Drug
Swiss CDMO Lonza has signed an agreement for the large-scale manufacture of the main drug intermediate for Swedish specialty pharma Oasmia’s investigational cancer drug candidate Cantrixil.
Lonza Completes API Expansion in China
Swiss CDMO Lonza has completed a planned laboratory expansion at its active pharmaceutical ingredients (API) manufacturing site at Nansha, China and plans to begin operation on Mar. 22.
Lonza and HaemaLogiX Link on Cancer Drug
Lonza has agreed a manufacturing partnership with Australian biotech HaemaLogiX for the latter’s lead multiple myeloma drug candidate KappaMab.
Lonza and Bioqube in Biologics Pact
Swiss CDMO Lonza has agreed a five-year collaboration on the development and manufacturing of biologics and small molecules with European venture capital firm Bioqube Ventures.
Lonza Adds Microbial Development Facilities at Visp
CDMO Lonza is adding microbial development capabilities at its Visp, Switzerland, site. The company said the investment will support a capacity increase services targeting microbial-derived proteins. Both the expanded laboratory space and the new equipment should be in place by the end of this year.
Arxada and Troy Merger Would Add Muscle in Microbial Control
Swiss specialty chemicals producer Arxada, which was recently sold by CDMO Lonza to private equity funds Bain Capital and Cinven, has made its first strategic move since the separation in July. The fledgling company has announced plans to merge with Troy Corporation, a globally oriented US player in microbial control.
